Quick Takeaways: Why It Matters? Gallant’s positive UMSC pilot data and FDA CVM’s expanded conditional approval eligibility together position this program as a potential first‑in‑class, disease‑modifying biologic in an almost empty feline OA toolbox. By showing up to...
Quick Takeaways Why It Matters? Merck Animal Health strengthens its dermatology franchise with a differentiated, second-generation JAK inhibitor positioned as a convenient, first-line option for allergic pruritus. Once-daily dosing and rapid onset are likely to ...
Quick Takeaways: Why It Matters? Full approval elevates KBroVet from a conditional option to the reference standard for potassium bromide in canine idiopathic epilepsy, giving vets greater confidence in its long‑term use. Its once‑daily, chewable, liver...
Quick Takeaways: Why It Matters? Full approval and label expansion make Vetmedin the standard of care for early-stage MMVD, locking in pimobendan as the only FDA‑approved option for delaying CHF in Stage B2 dogs and driving guideline‑aligned, earli...
Dechra Secures FDA Approval for Zygolide (Pergolide) in Equine Pituitary Pars Intermedia Dysfunction
Quick Takeaways: Why It Matters? Zygolide gives vets and owners a lower-cost, FDA-approved alternative for managing PPID, which should improve treatment uptake in senior horses. The focus on flexible dosing and palatability makes long-term therapy more practical in th...
